scholarly journals Routine Bone Imaging for Metastatic Renal Cell Carcinoma

2021 ◽  
Vol 8 (4) ◽  
pp. 20-21
Author(s):  
Mamta Parikh

Current guidelines by the National Comprehensive Cancer Network recommend that, in addition to routine computed tomography (CT) imaging, bone imaging and brain magnetic resonance imaging (MRI) should be obtained when clinically indicated. In this issue of the Journal of Kidney Cancer and VHL, a systematic literature review of clinical trials of metastatic renal cell carcinoma (mRCC) patients evaluates the incidence of osseous, lymph node and lung metastases. In particular, the analysis focuses on the changes in incidence over time. The study finds that the incidence of bone, lymph node, and lung metastases has increased over time, and that increases is significant in osseous metastases specifically. These results lead to two provocative questions. First, why have osseous metastases increased in incidence over time? Second, does this finding warrant a more aggressive and uniform approach to imaging to identify osseous metastases sooner?

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Brian F. Chapin ◽  
Scott E. Delacroix ◽  
Patrick A. Kemney ◽  
Graciela M. Nogueras-Gonzalez ◽  
Pheroze Tamboli ◽  
...  

2017 ◽  
Vol 49 (12) ◽  
pp. 2143-2149 ◽  
Author(s):  
Michele Marchioni ◽  
Marco Bandini ◽  
Raisa S. Pompe ◽  
Zhe Tian ◽  
Tristan Martel ◽  
...  

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15603-e15603 ◽  
Author(s):  
Marijana Jazvic ◽  
Jasna Radic ◽  
Zeljko Soldic ◽  
Ante Bolanca ◽  
Zvonko Kusic

e15603 Background: Five-years survival of patients with metastatic renal cell carcinoma (mRCC) is only 10%. A complete response (CR) to therapy is rare but has been achieved in minority of patients using high-dose interleukin-2. Sunitinib is an oral multitargeted receptor tyrosin kinase inhibitor and is currently considered the standard of care for first-line therapy of mRCC. CRs and long-term responders (LTR) to sunitinib have been documented in the literature. However, a detailed description and analysis of these patients is lacking. We report LTR, defined as patients achieving ongoing CR or remaining progression-free for ≥ 18 months on sunitinib. Methods: From 10/2008 till 12/2012, 48 patients were treated with sunitinib (50 mg/day, 4 weeks on/2 weeks off) as the first line therapy of clear cell mRCC. Tumor assessments were performed at baseline and every two cycles thereafter until the end of treatment, using RECIST criteria. Results: Nine patients were identified as LTR (18.8%). Retrospective data of these patients are reported in the Table. Conclusions: Sunitinib achieves LTR in a subset of patients with mRCC. Lung metastases and favourable MSKCC risk group may predict LTR. Maintaining full-dose sunitinib and management of therapy- related toxicity are crucial for treatment efficacy. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document